Company overview
etherna is a Belgian biotech company specializing in nucleic acid-based medicines, particularly mRNA therapeutics and customizable Lipid Nanoparticles (cLNPs) for targeted delivery. They provide development and manufacturing support to partners creating therapeutics and vaccines, with expertise in RNA chemistry and process technologies. Their platforms enable scalable, high-quality production, including lyophilized mRNA/LNP formulations, and have shown preclinical success in cancer immunotherapy.
etherna - mRNA-LNP delivery platforms is listed in the NovaPharmaNews Supplier Hub in the life-science supply chain serving United States & Americas. Core focus areas include mrna technology, lnp delivery, nucleic acid medicines, cancer immunotherapy, rna vaccines.
Structured facts
- Website
- https://www.etherna.be
- Markets served
- United States & Americas
- Keywords
- mrna technology, lnp delivery, nucleic acid medicines, cancer immunotherapy, rna vaccines
Products & technologies
Therapeutic areas
Markets served
Company timeline
- — Profile published on NovaPharmaNews
Frequently asked questions
- What are etherna's core technology platforms?
- etherna offers advanced mRNA platforms for optimization and selection, along with customizable Lipid Nanoparticles (cLNPs) for extrahepatic delivery, supported by RNA chemistry and process technologies.
- What therapeutic areas does etherna target?
- etherna focuses on nucleic acid-based medicines for cancer immunotherapy, infectious diseases, and vaccines, with preclinical data showing tumor regression in models like triple-negative breast cancer.
- Where is etherna headquartered and what is their regulatory experience?
- Headquartered in Niel, Belgium, etherna supports partners in development and manufacturing of nucleic acid therapeutics; they have advanced platforms like LAD116 to clinical stages.
Related editorial coverage
- Personalized mRNA Cancer Vaccines: A New Era for Melanoma Treatment
- MacroGenics Expands ZYNYZ Royalty Agreement with Sagard Healthcare Partners for Cancer Drug
- Greenwich LifeSciences GLSI-100 Abstract Accepted at ASCO 2026 for Breast Cancer Immunotherapy Trial
Explore lab tools and QA/QC resources for R&D teams.
